<DOC>
	<DOC>NCT02181842</DOC>
	<brief_summary>The purpose of this survey is to evaluate the effects on glycemic control and to evaluate the safety of long-term use of pioglitazone tablets (Actos Tablets) in type 2 diabetic patients with inadequate glycemic control and a prior history of cerebral infarction.</brief_summary>
	<brief_title>Pioglitazone Tablets Specified Drug-use Survey &lt;Survey on Glycemic Control in Type 2 Diabetic Patients With a History of Cerebral Infarction&gt;</brief_title>
	<detailed_description>This survey was designed to evaluate the effects on glycemic control and to evaluate the safety of long-term use of pioglitazone tablets (Actos Tablets) in type 2 diabetic patients with inadequate glycemic control and a prior history of cerebral infarction. For adults, 15-30 mg of pioglitazone is usually administered orally once daily before or after breakfast. The dose should be adjusted depending on sex, age, and symptoms; however, the maximum daily dose should not exceed 45 mg.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Type 2 diabetic patients with a prior history of cerebral infarction who meet all the following conditions, [1] to [3], at the time of enrollment in the survey: 1. First onset of cerebral infarction was at least 24 weeks prior to enrollment 2. HbA1c values ≥ 6.5% within 12 weeks prior to the start of treatment with Actos Tablets 3. No prior history of treatment with Actos Tablets since the first onset of cerebral infarction Patients who meet any of the following conditions, [1] to [5], shall be excluded from the survey: 1. Contraindication for Actos Tablets 2. Prior history of recurrence of cerebral infarction 3. Prior history of cerebral hemorrhage or subarachnoid hemorrhage 4. Complications or prior history of myocardial infarction, angina pectoris, cardiomyopathy, hypertensive heart disease, atrial fibrillation, atrial flutter, or valvular disease 5. Reduced cardiac function (defined as an ejection fraction [EF] ≤ 40%)</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Pharmacological therapy</keyword>
</DOC>